Hong Kong stock abnormal | CanSino Biologics (06185.HK) rose over 5%, Phase I clinical trial of inhaled tuberculosis vaccine launched in Indonesia

According to the info obtained by the Capital Online APP, CanSino Biologics (06185.HK) has risen by more than 5%, and as of the time of publication, it has increased by 5.03% to 46.38 Hong Kong dollars, with a trading volume of 16.1181 million Hong Kong dollars.